Roche Venture Fund

Roche Venture Fund accounts for 24 tracked companies with verified cap-table data, 24 of which disclose round sizes totalling $5.2B. The median disclosed raise is $114M, and the largest is Vaxcyte at $2.4B, ahead of Endeavor BioMedicines ($292M) and Arch Oncology ($241M).

The names that recur most often on these portfolio cap tables are Roche Venture Fund (24 companies), 5AM Ventures (5 companies), Sofinnova Partners (4 companies), Versant Ventures (3 companies), Novo Holdings (3 companies), Ysios Capital (3 companies). By latest disclosed round, the market skews Series A (12), Series B (6), Series C (3), IPO (1).

• Companies tracked: 24
• Disclosed funding total: $5.2B across 24 companies
• Median disclosed raise: $114M
• Largest raise: Vaxcyte — $2.4B
• Stage mix: Series A 12 · Series B 6 · Series C 3 · IPO 1
• Most recent dated round: 2026-05-18

Best funded Roche Venture Fund companies

1. Vaxcyte — $2.4B (latest: IPO)
2. Endeavor BioMedicines — $292M (latest: Series A)
3. Arch Oncology — $241M (latest: Series C)
4. Entrada Therapeutics — $241M (latest: Series A)
5. Aligos Therapeutics — $225M (latest: Series B)
6. Epic Sciences — $196M
7. Black Diamond Therapeutics — $194M (latest: Series C)
8. GlycoEra — $179M (latest: Series B)
9. Splice Bio — $170M (latest: Series B)
10. Minoryx Therapeutics — $138M (latest: Series C)
11. Cour Pharmaceuticals Development — $135M (latest: Series A)
12. MISSION Therapeutics — $114M (latest: Series A)
13. IDEAYA Biosciences — $94M (latest: Series B)
14. Bonum Therapeutics — $93M (latest: Series A)
15. NMD Pharma — $79M (latest: Series B)

Roche Venture Fund — related firms and companies (56)

• Vaxcyte
• Endeavor BioMedicines
• Arch Oncology
• Entrada Therapeutics
• Aligos Therapeutics
• Epic Sciences
• Black Diamond Therapeutics
• GlycoEra
• Investors like Next47
• Investors like Tiger Global Management
• Investors like Bond
• Investors like Service Provider Capital
• Investors like Insight Partners
• Investors like Primary Venture Partners
• Investors like Greycroft
• Investors like Canapi Ventures
• Investors like ARCH Venture Partners
• Investors like First Round Capital
• Investors like Roche Venture Fund
• Enthera
• Soteria Biotherapeutics
• Pandion Therapeutics
• Bonum Therapeutics
• Cour Pharmaceuticals Development
• Investors like Norwest Venture Partners
• Investors like Recursive Ventures
• Firms like GV
• Investors like General Catalyst
• Investors like Point72 Ventures
• Investors like Spark Capital
• Investors like Ribbit Capital
• Investors like Maveron
• Investors like Founders Fund
• Investors like Storm Ventures
• Investors like Correlation Ventures
• Companies backed by Roche Venture Fund
• Purigen Biosystems
• Vivet Therapeutics
• Aileron Therapeutics
• NMD Pharma
• MISSION Therapeutics
• Splice Bio
• Investors like Vine Ventures
• Investors like ACME Capital
• Investors like Greylock
• Investors like Shasta Ventures
• Investors like Sapphire Ventures
• Investors like White Star Capital
• Investors like Crossbeam Venture Partners
• Investors like True Ventures
• Investors like StepStone Group
• Investors like Meritech Capital Partners
• Investors like Zetta Venture Partners
• Roche Venture Fund co-investors 2026
• DiogenX
• Mironid

Roche Venture Fund alternatives · All research reports